Evidence map›Paper›PMID 38085264›Full record

ArticleEuropean journal of neurology2024

Abnormal dopamine transporter imaging in pure autonomic failure: a potential biomarker of central nervous system involvement.

Rana Alnasser Alsukhni, Ekawat Vichayanrat, Shiwen Koay, Laura May Davis, Gordon Ingle, Patricia McNamara, Jalesh N Panicker, Kailash P Bhatia, Christopher Mathias, Jamshed Bomanji and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Rana Alnasser AlsukhniAutonomic Unit, National Hospital for Neurology and Neurosurgery, London, UK.ORCID 0000-0002-1737-9577
Ekawat VichayanratAutonomic Unit, National Hospital for Neurology and Neurosurgery, London, UK.
Shiwen KoayAutonomic Unit, National Hospital for Neurology and Neurosurgery, London, UK.
Laura May DavisInstitute of Nuclear Medicine, UCLH NHS Foundation Trust, London, UK.
Gordon IngleAutonomic Unit, National Hospital for Neurology and Neurosurgery, London, UK.
Patricia McNamaraAutonomic Unit, National Hospital for Neurology and Neurosurgery, London, UK.
Jalesh N PanickerUCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
Kailash P BhatiaDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.
Christopher MathiasUCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
Jamshed BomanjiInstitute of Nuclear Medicine, UCLH NHS Foundation Trust, London, UK.
Valeria IodiceAutonomic Unit, National Hospital for Neurology and Neurosurgery, London, UK.
National Hospital for Neurology and Neurosurgery · GBEast London NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposePure autonomic failure (PAF) is a rare progressive neurodegenerative disease characterized by neurogenic orthostatic hypotension at presentation, without other neurological abnormalities. Some patients may develop other central neurological features indicative of multiple system atrophy or a Lewy body disorder. There are currently no biomarkers to assess possible central nervous system involvement in probable PAF at an early stage. A possibility is to evaluate the nigrostriatal dopaminergic degeneration by imaging of dopamine transporter with DaTscan brain imaging. The objective was to evaluate subclinical central nervous system involvement using DaTscan in PAF.

methodsWe retreospectively reviewed pure autonomic failure patients who were evaluated at the Autonomic Unit between January 2015 and August 2021 and underwent comprehensive autonomic assessment, neurological examination, brain magnetic resonance imaging and DaTscan imaging. DaTscan imaging was performed if patients presented with atypical features which did not meet the criteria for Parkinson's disease or multiple system atrophy or other atypical parkinsonism.

resultsIn this cohort, the median age was 49.5 years at disease onset, 57.5 years at presentation, and the median disease duration was 7.5 years. Five of 10 patients had an abnormal DaTscan without neurological features meeting the criteria of an alternative diagnosis. Patients with abnormal DaTscan were predominantly males, had shorter disease duration and had more severe genitourinary symptoms. DISCUSSION: Degeneration of nigrostriatal dopaminergic neurons measured using DaTscan imaging can present in patients with PAF without concurrent signs indicating progression to widespread α-synucleinopathy. It is advocated that DaTscan imaging should be considered as part of the workup of patients with emerging autonomic failure who are considered to have PAF.

Indexed as

Autonomic Nervous System DiseasesMultiple System AtrophyPure Autonomic FailureBiomarkersBrainDopamine Plasma Membrane Transport ProteinsDopaminergic ImagingFemaleHumansMaleMiddle AgedBiomarkersDopamine Plasma Membrane Transport Proteinscentral involvementDaTscandopamine transporterphenoconversionpure autonomic failure

Identifiers

PMID38085264
PMCPMC11235633
OpenAlexW4389639607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.